Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

SALMETEROL XINAFOATE

All products: Limited Use (codes 132, 391)

Other products in the same Health Canada class (R03A, R03AC) — coverage varies; not interchangeable

  • Salbutamol (Teva-Salbutamol Sterinebs P.F.): general benefit, Limited Use 256, 257, 258, 259, Limited Use 265, 266, 267, 268, Not a benefit
  • Terbutaline (Bricanyl Turbuhaler): general benefit
  • Formoterol (Foradil): limited Use 132
  • Formoterol (Oxeze Turbuhaler): limited Use 132
  • Indacaterol (Onbrez Breezhaler): limited Use 443
  • Aclidinium + formoterol (Duaklir Genuair): limited Use 459

8 more in the class list below

SereVent Diskus · DIN 02231129 · 50mcg · dry-powder inhaler, 60 doses

Limited Use — Reason for Use code 132, 391 requiredMarketed · checked 2026-09-02
StatusLimited Use — Reason for Use code 132, 391 required
Write on scriptLU code 132, 391 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 132, 391
Reason for Use code 132 For the treatment of asthma in patients who are using optimum anti-inflammatory treatment and are still experiencing breakthrough symptoms. Coverage limit: This drug is not for relief of acute symptoms. Coverage limit: LU Authorization Period: Indefinite Reason for Use code 391 For patients with moderate to severe COPD with persistent respiratory symptoms despite an adequate trial of, or an intolerance to, a regularly scheduled short-acting bronchodilator AND a long-acting anticholinergic. Coverage limit: LU Authorization Period: Indefinite
No interchangeable product listed in the Ontario extract
SereVent Diskus · DIN 02231129 Manufacturer: GlaxoSmithKline Inc., GlaxoSmithKline Consumer Health Care; listing date 1998-12-31 Health Canada: Marketed since 2003-01-16 · brand SEREVENT DISKUS (50MCG/DOSE) · ATC R03AC12 SALMETEROL · form Powder · route Inhalation · ingredients SALMETEROL (SALMETEROL XINAFOATE) 50 MCG/ACT · company Glaxosmithkline inc · schedule Prescription
Check this DIN again · Health Canada product record

SereVent Diskus: Formulary list price $81.0700/unit (unit not stated in source; not the patient's cost)

Ministry pays: $81.0700 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=50436 · Verify on the e-Formulary ↗ (DIN 02231129)

Source record
DIN 02231129: SereVent Diskus Raw flags: sec12=Y, sec3=Y Item: 121200077; group id 236; item number 0418; lccId 00043; manufacturer id GSK Source form: Pd Inh-60 Dose Pk; strength: 50mcg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $81.0700; ministry $81.0700 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02231129 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=50436
Shortage status: resolved shortage (ended 2025-10-01); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02231129
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Other drugs in the same formulary class (12:12 Sympathomimetic (Adrenergic) Agents) and how they are covered

Matched class: 12:12 Sympathomimetic (Adrenergic) Agents

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: EPINEPHRINE HCL, TERBUTALINE SULFATE Some products covered without a code (check the product listing): ORCIPRENALINE SULFATE, SALBUTAMOL 12:12 Sympathomimetic (Adrenergic) Agents

SALBUTAMOL

· 20 products · Limited Use, codes 265, 266, 267, 268 (4), Listed, not a benefit (8), Limited Use, codes 256, 257, 258, 259 (1), General benefit (7) · strengths: 1mg/mL, 2mg/mL, 5mg/mL, 100mcg/Metered Dose, 2mg, 4mg · Inh Sol- 2.5mL Pk, Inh Sol-10mL Pk, Inh-200 dose Pk, Tab

TERBUTALINE SULFATE

· 2 products · General benefit · strengths: 0.5mg/Dose · Inh-100 Dose Pk, Inh-120 Dose Pk

FORMOTEROL FUMARATE

· 1 products · Limited Use, codes 132 · strengths: 12mcg/Cap · Inh Pd-Device Pk

FORMOTEROL FUMARATE DIHYDRATE

· 2 products · Limited Use, codes 132 · strengths: 6mcg/Metered Dose, 12mcg/Metered Dose · Pd Inh-60 Dose Pk

INDACATEROL

· 1 products · Limited Use, codes 443 · strengths: 75mcg · Inh Pd-Cap

ACLIDINIUM BROMIDE & FORMOTEROL FUMARATE DIHYDRATE

· 1 products · Limited Use, codes 459 · strengths: 400mcg & 12mcg · Metered Dose Pd Inh-60 Dose Pk

BUDESONIDE & FORMOTEROL FUMARATE DIHYDRATE

· 2 products · Limited Use, codes 330 · strengths: 100mcg/6mcg, 200mcg/6mcg · Pd Inh-120 Dose Pk

BUDESONIDE&GLYCOPYRRONIUM (GLYCOPYRRONIUM BROMIDE)&FORMOTEROL FUMARATE DIHYDRATE

· 1 products · Limited Use, codes 638 · strengths: 160mcg & 7.2mcg & 5mcg/Act · Metered Dose Inh-120 Dose Pk

FLUTICASONE FUROATE & UMECLIDINIUM BROMIDE & VILANTEROL TRIFENATATE

· 1 products · Limited Use, codes 567 · strengths: 100mcg & 62.5mcg & 25mcg · Pd Inh-30 Dose Pk

FLUTICASONE FUROATE & VILANTEROL

· 2 products · Limited Use, codes 330, 456 (1), Limited Use, codes 330 (1) · strengths: 100mcg & 25mcg, 200mcg & 25mcg · Blister Pd Inh-30 Dose Pk

INDACATEROL & GLYCOPYRRONIUM

· 1 products · Limited Use, codes 459 · strengths: 110mcg & 50mcg · Inh Pd-Cap

MOMETASONE FUROATE & FORMOTEROL FUMARATE DIHYDRATE

· 2 products · Limited Use, codes 330 · strengths: 100mcg & 5mcg, 200mcg & 5mcg · Metered Dose Inh-120 Dose Pk Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 12:12 and 4 more
Full class listing Related classes: 12:04 Parasympathomimetic (Cholinergic) Agents, 12:08 Parasympatholytic (Cholinergic Blocking) Agents, 12:20 Skeletal Muscle Relaxants Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1 INDICATIONS Asthma SEREVENT DISKUS (salmeterol xinafoate) is indicated for the treatment of asthma only as add-on therapy to an inhaled corticosteroid; a long-term asthma control medication; in patients 4 years of age and older with reversible obstructive airway disease, including patients with nocturnal asthma. Corticosteroids should not be stopped because salmeterol is prescribed. Long-acting beta2-adrenergic agonists (LABA), such as salmeterol, the active ingredient in SEREVENT DISKUS, increase the risk of asthma-related death (see WARNINGS AND PRECAUTIONS). Use of SEREVENT DISKUS for the treatment of asthma without concomitant use of an inhaled corticosteroid; a long-term asthma control medication; is contraindicated (see CONTRAINDICATIONS). Use SEREVENT DISKUS only as add-on therapy for patients with asthma who are currently taking but are inadequately controlled on an inhaled corticosteroid. Once asthma control is achieved and maintained, assess the patient at regular intervals. If possible without loss of asthma control, discontinue SEREVENT DISKUS and maintain the patient on an inhaled corticosteroid; a long-term asthma control medication. Do not use SEREVENT DIS… https://pdf.hres.ca/dpd_pm/00060366.PDF PM date: March 2, 2021 Source product: SEREVENT DISKUS (50MCG/DOSE); DIN 02231129; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.